Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
186.78B
Market cap186.78B
Price-Earnings ratio
23.76
Price-Earnings ratio23.76
Dividend yield
2.86%
Dividend yield2.86%
Average volume
2.38M
Average volume2.38M
High today
$349.54
High today$349.54
Low today
$331.00
Low today$331.00
Open price
$340.75
Open price$340.75
Volume
3.59M
Volume3.59M
52 Week high
$391.29
52 Week high$391.29
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

The current Amgen(AMGN) stock price is $342.00, with a market capitalization of 186.78B. The stock trades at a price-to-earnings (P/E) ratio of 23.76 and offers a dividend yield of 2.9%.

On 2026-04-30, Amgen(AMGN) stock traded between a low of $331.00 and a high of $349.54. Shares are currently priced at $342.00, which is +3.3% above the low and -2.2% below the high.

The Amgen(AMGN)'s current trading volume is 3.59M, compared to an average daily volume of 2.38M.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

During the past year, Amgen(AMGN) stock moved between $261.43 at its lowest and $391.29 at its peak.

AMGN News

The Motley Fool 2h
Amgen Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, April 30, 2026 at 4:30 p.m. ET Call participants Chairman & Chief Executive Officer — Robert A. Bradway Executive Vice...

Amgen Q1 2026 Earnings Transcript
The Wall Street Journal 4h
Amgen Posts Higher First-Quarter Profit, Revenue

Amgen’s product sales were up 4%, led by 9% growth in product volume. Clodagh Kilcoyne / Reuters Amgen AMGN 2.43 %increase; green up pointing triangle said its...

Amgen Posts Higher First-Quarter Profit, Revenue
TipRanks 4h
Amgen reports Q1 adjusted EPS $5.15, consensus $4.77

Reports Q1 revenue $8.6B, consensus $8.57B. “Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, e...

Analyst ratings

51%

of 37 ratings
Buy
40.5%
Hold
51.4%
Sell
8.1%

More AMGN News

TipRanks 4h
Amgen sees FY26 CapEx $2.6B; share repurchases not to exceed $3B

16:03 EDT Amgen (AMGN) sees FY26 CapEx $2.6B; share repurchases not to exceed $3B Published first on TheFly – the ultimate source for real-time, market-moving...

Investor's Business Daily 4h
Amgen's Numbers Are Out: It Gets To Keep Its Cholesterol Crown — For Now

Technology Amgen's Numbers Are Out: It Gets To Keep Its Cholesterol Crown — For Now Licensing Amgen (AMGN) widely beat the Street's first-quarter expectations l...

Amgen's Numbers Are Out: It Gets To Keep Its Cholesterol Crown — For Now
Simply Wall St 21h
FDA Tavneos Proposal Puts Amgen Trial Integrity And Growth Story Under Review

The FDA's Center for Drug Evaluation and Research has proposed that Amgen withdraw its drug Tavneos, citing untrue statements of material facts and possible dat...

FDA Tavneos Proposal Puts Amgen Trial Integrity And Growth Story Under Review
Seeking Alpha 1d
Amgen Q1 Preview: What to expect

Amgen (AMGN) is projected to report a nearly 3% fall in its Q1 earnings on April 30, after the closing bell. The consensus EPS Estimate is $4.77, while the rev...

Amgen Q1 Preview: What to expect
TipRanks 2d
FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results to accelerate...

Seeking Alpha 2d
Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

The U.S. FDA has proposed to withdraw the marketing of Tavneos, a treatment developed by Amgen (AMGN) for a group of rare disorders called anti-neutrophil cytop...

Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.